China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
This article was originally published in PharmAsia News
Executive Summary
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.